Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene ( WT1 ) product

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1991 • 3,493 citations

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

1990 • 1,882 citations

Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene

1985 • 1,804 citations

MHC ligands and peptide motifs: first listing

1995 • 1,674 citations

Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping

1990 • 1,300 citations

Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells

1993 • 1,219 citations

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

1994 • 921 citations

Rosette-Forming Human Lymphoid Cell Lines. I. Establishment and Evidence for Origin of Thymus-Derived Lymphocytes<xref ref-type="fn" rid="FN1">2</xref>

1972 • 916 citations

Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity

1990 • 904 citations

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1992 • 855 citations

Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines

1994 • 841 citations

Establishment and characterization of a unique human cell line that proliferates dependently on GM‐CSF, IL‐3, or erythropoietin

1989 • 833 citations

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

1992 • 694 citations

A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.

1985 • 607 citations

WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia

1994 • 575 citations

Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells

1994 • 545 citations

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

1995 • 542 citations

Repression of the Insulin-Like Growth Factor II Gene by the Wilms Tumor Suppressor WT1

1992 • 535 citations

Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

1994 • 467 citations

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

1995 • 446 citations

Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid.

1986 • 437 citations

Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes

1994 • 421 citations

Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.

1995 • 387 citations

Presentation of viral antigen controlled by a gene in the major histocompatibility complex

1990 • 381 citations

A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3

1994 • 379 citations

Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia

1997 • 375 citations

Expression of the Wilms' tumor gene (WT1) in human leukemias.

1992 • 354 citations

Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ

1990 • 343 citations

Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells

1996 • 341 citations

Targeting p53 as a general tumor antigen.

1995 • 315 citations

Specific human cellular immunity to bcr-abl oncogene-derived peptides

1996 • 300 citations

Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product.

1993 • 268 citations

Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis

1996 • 268 citations

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

1993 • 267 citations

Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.

1995 • 263 citations

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

1994 • 254 citations

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

1998 • 244 citations

T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I–E

1989 • 238 citations

Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601

1994 • 233 citations

Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.

1992 • 226 citations

Expression of the Wilms' Tumor Gene WT1 in Solid Tumors and Its Involvement in Tumor Cell Growth

1999 • 216 citations

Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.

1991 • 208 citations

Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels

1996 • 187 citations

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

1996 • 185 citations

T-cell immunity to the joining region of p210BCR-ABL protein.

1992 • 184 citations

Wilms' Tumor Gene (WT1) Competes With Differentiation-Inducing Signal in Hematopoietic Progenitor Cells

1998 • 178 citations

Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis.

1997 • 172 citations

An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein.

1991 • 172 citations

Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus.

1993 • 171 citations

A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.

1993 • 171 citations

Carbohydrate moiety of HLA antigens. Antigenic properties and amino acid sequences around the site of glycosylation.

1977 • 169 citations

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.

1994 • 168 citations

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

1997 • 163 citations

Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.

1997 • 157 citations

Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells.

1993 • 152 citations

Limit of T Cell Tolerance to Self Proteins by Peptide Presentation

1990 • 138 citations

T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.

1991 • 126 citations

CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells.

1995 • 124 citations

The Wilms' Tumor 1 Gene: Oncogene or Tumor Suppressor Gene?

1998 • 121 citations

T‐Cell Immunotherapy of Tumors by Adoptive Transfer of Cytotoxic T Lymphocytes and by Vaccination with Minimal Essential Epitopes

1995 • 115 citations

The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells.

1994 • 115 citations

The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro.

1997 • 115 citations

Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA‐A2 in its recognition by cytotoxic T lymphocytes

1992 • 114 citations

Constitutive expression of the Wilms’ tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)

1999 • 99 citations

Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells.

1993 • 95 citations

p53, a potential target for tumor-directed T cells

1994 • 88 citations

Wilms' Tumor Gene Expression in Human CD34+ Hematopoietic Progenitors During Fetal Development and Early Clonogenic Growth

1997 • 67 citations

Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia [letter]

1996 • 60 citations

Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms

1998 • 60 citations

Antiidiotype antibody therapy of B-cell lymphoma.

1989 • 52 citations

Breaking immunologic ignorance to an antigenic peptide of simian virus 40 large T antigen.

1995 • 44 citations

A Simple Method of Detecting Amplified DNA with Immobilized Probes on Microtiter Wells

1993 • 39 citations

Cytotoxic T lymphocyte responses to wild‐type and mutant mouse p53 peptides

1997 • 21 citations

Induction of anti-allo-class I H-2 tolerance by inactivation of CD8+ helper T cells, and reversal of tolerance through introduction of third-party helper T cells.

1990 • 17 citations

Allele typing of HLA-A10 group by nested-PCR-low ionic strength single stranded conformation polymorphism and a novel A26 allele (A26KY, A∗2605)

1996 • 10 citations